Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

346 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A prospective randomized controlled trial of structured treatment interruption in HIV-infected patients failing highly active antiretroviral therapy (Canadian HIV Trials Network Study 164).
Walmsley SL, Thorne A, Loutfy MR, LaPierre N, MacLeod J, Harrigan R, Trottier B, Conway B, Hay JR, Singer J, Zarowny D. Walmsley SL, et al. Among authors: loutfy mr. J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):418-25. doi: 10.1097/QAI.0b013e318061b611. J Acquir Immune Defic Syndr. 2007. PMID: 17468667 Clinical Trial.
Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control.
Ferreira MA, Mangino M, Brumme CJ, Zhao ZZ, Medland SE, Wright MJ, Nyholt DR, Gordon S, Campbell M, McEvoy BP, Henders A, Evans DM, Lanchbury JS, Pereyra F; International HIV Controllers Study; Walker BD, Haas DW, Soranzo N, Spector TD, de Bakker PI, Frazer IH, Montgomery GW, Martin NG. Ferreira MA, et al. Am J Hum Genet. 2010 Jan;86(1):88-92. doi: 10.1016/j.ajhg.2009.12.008. Epub 2009 Dec 31. Am J Hum Genet. 2010. PMID: 20045101 Free PMC article.
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.
Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BY; BENCHMRK Study Teamsa. Steigbigel RT, et al. Among authors: loutfy mr. Clin Infect Dis. 2010 Feb 15;50(4):605-12. doi: 10.1086/650002. Clin Infect Dis. 2010. PMID: 20085491 Free PMC article. Clinical Trial.
Cohort profile: the Canadian Observational Cohort collaboration.
Palmer AK, Klein MB, Raboud J, Cooper C, Hosein S, Loutfy M, Machouf N, Montaner J, Rourke SB, Smieja M, Tsoukas C, Yip B, Milan D, Hogg RS; CANOC Collaboration. Palmer AK, et al. Int J Epidemiol. 2011 Feb;40(1):25-32. doi: 10.1093/ije/dyp393. Epub 2010 Feb 15. Int J Epidemiol. 2011. PMID: 20157000 No abstract available.
Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries.
Raboud JM, Loutfy MR, Su D, Bayoumi AM, Klein MB, Cooper C, Machouf N, Rourke S, Walmsley S, Rachlis A, Harrigan PR, Smieja M, Tsoukas C, Montaner JS, Hogg RS; CANOC Collaboration. Raboud JM, et al. Among authors: loutfy mr. BMC Infect Dis. 2010 Feb 25;10:40. doi: 10.1186/1471-2334-10-40. BMC Infect Dis. 2010. PMID: 20184766 Free PMC article.
Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort.
Cescon AM, Cooper C, Chan K, Palmer AK, Klein MB, Machouf N, Loutfy MR, Raboud J, Rachlis A, Ding E, Lima VD, Montaner JS, Rourke SB, Smieja M, Tsoukas C, Hogg RS; CANOC Collaboration. Cescon AM, et al. Among authors: loutfy mr. HIV Med. 2011 Jul;12(6):352-60. doi: 10.1111/j.1468-1293.2010.00890.x. Epub 2010 Nov 8. HIV Med. 2011. PMID: 21059167 Free article.
346 results